Capital and Coast District Health Board logo

ABBVIE GBM13-813 First line treatment with patients with newly diagnosed GBM and EGFR amplification.

A Randomized, Placebo Controlled Phase 2b/3 Study of ABT-414 with Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects with Newly Diagnosed Glioblastoma (GBM) with Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance 1)

This trial is currently recruiting.

Phone: Debra Morriss 9186106

Email: Debra.morriss@ccdhb.org.nz

Trial website: https://clinicaltrials.gov/ct2/show/NCT02573324

 

Trial purpose: This study seeks to determine whether the addition of ABT-414 to concomitant radiotherapy and temozolomide (TMZ) prolongs progression free survival (PFS) and overall survival (OS) in participants with newly diagnosed glioblastoma (GBM) with epidermal growth factor receptor (EGFR) amplification.

In addition, there is a Phase 1, open-label, multicenter sub-study to assess the pharmacokinetics, safety and tolerability of ABT-414 in subjects with newly diagnosed EGFR-amplified GBM who have mild or moderate hepatic impairment.

ABBVIE M15-889: For the treatment of patients with relapsed or refractory chronic lymphocytic leukaemia

Open-Label, Single Arm, Phase 3b, Multi-Center Study Evaluating the Impact of Venetoclax on the Quality of Life of Relapsed/Refractory Subjects with Chronic Lymphocytic Leukemia (CLL) Including those with the 17p Deletion or TP53 Mutation OR Those Who Have Received Prior Treatment with a B-Cell Receptor Inhibitor.

This trial is currently recruiting.

Phone: Debra Morriss 9186106

Email: Debra.morriss@ccdhb.org.nz

Trial website: https://clinicaltrials.gov/ct2/show/NCT02980731

AML-Li-1 First line treatment for patients with acute myeloid leukaemia in the older age group.

A programme of development for older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome.

This trial is currently recruiting. 

Phone: Sushi Geller 9186105

Email: Sushi.geller@ccdhb.org.nz

Trial Website: http://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-sapacitabine-AC220-vosaroxin-cytarabine-acute-myeloid-leukaemia-aml-li-1

ET743-OVC-3006 Third line treatment for patients with ovarian Cancer

A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

This study is currently recruiting participants.

Phone: Maureen Blakemore 918-6103

Email: Maureen.blakemore@ccdhb.org.nz

Trial website: https://clinicaltrials.gov/show/NCT01846611 

Trial purpose: The purpose of this study is to assess the efficacy and safety of trabectedin+DOXIL as a third-line chemotherapy regimen (treatment) in patients with platinum-sensitive advanced-relapsed epithelial ovarian, primary peritoneal, or fallopian tube cancer who received 2 previous lines of platinum-based chemotherapy.

 

KINEX 002/KINEX 003 for patients who would receive weekly paclitaxel

A bioequivalence study of oraxol and intravenous paclitaxel. For patients who would receive weekly paclitaxel as standard of care.

 This trial is currently recruiting.

Phone: Susan Millmow 918-6109

Email: Susan_mary.millmow@ccdhb.org.nz

Trial Website: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=368745

https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=368755

KX-ORAX-002 Study Protocol Title: A Randomized Crossover Study to Determine the Bioequivalence of Three Consecutive Daily Doses of Oraxol in Cancer Patients Treated With Intravenous Paclitaxel KXORAX003 Safety Study of Oraxol (HM30181 + oral paclitaxel) in Cancer Patients.

 

MELVAC: for patients with stage II, III or IV fully resected melanoma

A phase II Trial of immunisation with autologous dendritic cells loaded with NY-ESO-1 and α-galactosylceramide in patients with high-risk surgically resected stage II, III or IV melanoma.

This trial is currently recruiting.

Phone: Tess Ostapowicz on 385 5110

Email: Tess.ostapowicz@ccdhb.org.nz

Trial websites: http://www.cancertrialsnz.ac.nz/melvac/ and https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=363134

MK 3475-412 for patients with locally advanced head and neck cancer

Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)

This study is currently recruiting participants.

Phone: Rosie Whitmore 9186109

Email: rosie.whitmore@ccdhb.org.nz

Trial website: https://clinicaltrials.gov/ct2/show/NCT03040999?term=MK+3475&cond=Head+and+Neck&cntry1=PA%3ANZ&rank=2 

Trial purpose: The purpose of this study is to determine the efficacy and safety of pembrolizumab given concomitantly with chemoradiation (CRT) and as maintenance therapy versus placebo plus CRT in participants with locally advanced head and neck squamous cell carcinoma (LA HNSCC). The primary hypothesis is that pembrolizumab in combination with CRT is superior to placebo in combination with CRT with respect to event-free survival (EFS) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by blinded independent central review (BICR).

ORCCYD – ET743-OVC Third line treatment for patients with advanced, relapsed Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer

ET743-OVC-3006 A randomised, Open-Label Study comparing the combination of YONDELIS and DOXIL/CAELYX Monotherapy for the treatment of Advanced Relapsed Epithelial Ovarian,Primary Peritoneal or Fallopian Tube Cancer.

This trial is currently recruiting.

Phone: Maureen Blakemore 918-6103

Email: Maureen.blakemore@ccdhb.org.nz

Trial websites: https://clinicaltrials.gov/ct2/show/NCT01846611 and https://www.smartpatients.com/trials/NCT01846611

 

Thirdline treatment for patients with advanced, relapsed Epithelial, Ovarian,Primary Peritoneal or Fallopian Tube Cancer.

OUTBACK for patients with locally advanced cervical cancer

Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer

This study is currently recruiting participants.

Phone: Debra Morriss 9186106

Email: debra.morriss@ccdhb.org.nz

Trial website: https://clinicaltrials.gov/ct2/show/NCT01414608 

Trial purpose: This randomized phase III trial studies how well giving cisplatin and radiation therapy together with or without carboplatin and paclitaxel works in treating patients with cervical cancer has spread from where it started to nearby tissue or lymph nodes. Drugs used in chemotherapy, such as cisplatin, carboplatin, and paclitaxel, work in different ways to stop the growth of [cancer/tumor] cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. External radiation therapy uses high-energy x rays to kill tumor cells. Internal radiation uses radioactive material placed directly into or near a tumor to kill tumor cells. It is not yet known whether giving cisplatin and external and internal radiation therapy together with carboplatin and paclitaxel kills more tumor cells.

RATIONAL For patients with acquired hypogammaglobulinemia secondary to haematological malignancies.

A randomised controlled feasibility trial comparing the efficacy of prophylactic immunoglobulin with prophylactic antibiotics in patients with acquired hypogammaglobulinemia secondary to haematological malignancies.

This trial is currently recruiting.

Phone: Sushi Geller 9186102

Email: sushi.geller@ccdhb.org.nz

Website: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=372003

TRILOGY: first line treatment for patients with locally advanced or metastatic melanoma

A Phase III, Double-Blinded, Randomized, Placebo Controlled Study Of Atezolizumab Plus Cobimetinib And Vemurafenib Versus Placebo Plus Cobimetinib And Vemurafenib In Previously Untreated Braf V600 Mutation Positive Patients With Unresectable Locally Advanced Or Metastatic Melanoma

Phone: Susan Millmow 918 6109

Email: Susan_mary.millmow@ccdhb.org.nz

Trial website: https://clinicaltrials.gov/ct2/show/NCT02908672

Last updated 10 October 2017.